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The role of peroxisome proliferator-activated receptor in the 
treatment of non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) has been defined as 
a spectrum of histological abnormalities and is characterized 
by significant and excessive accumulation of triglycerides in 
the hepatocytes in patients without alcohol consumption or 
other diseases. Current studies are targeting new molecular 
mechanisms that underlie NAFLD and associated metabolic 
disorders. Many therapeutic targets have been found and used 
in clinical studies. Peroxisome proliferator-activated receptors 
(PPARs) are among the potential targets and have been dem-
onstrated to exert a pivotal role in modulation of NAFLD. 
Many drugs developed so far are targeted at PPARs. Thus, the 
aim of this paper is to summarize the roles of PPARs in the 
treatment of NAFLD.
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Non-alcoholic fatty liver disease (NAFLD) is the commonest cause of liver disease in 
humans. Its main characteristic is excessive accumulation of triglycerides in the hepato-
cytes without consumption of alcohol or other drugs (1). NAFLD includes a wide variety 
of conditions, from simple steatosis to non-alcoholic steatohepatitis (NASH) and can even-
tually lead to cirrhosis, liver failure, and/or hepatocellular carcinoma (2, 3). According to 
the literature, about 10–29 % of NASH patients might progress to liver cirrhosis within 10 
years and about 4–27 % of liver cirrhosis patients might develop hepatocellular carcinoma 
(HCC) (Fig.  1) (4, 5). The diagnosis of NAFLD remains unclear because many patients are 
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major and also the most accurate tool to diagnose NAFLD. However, liver biopsy often 
carries a serious risk of complications (6). Hence, more research is needed to discover new 
drugs.
PATHOGENESIS OF NAFLD
The natural history and pathogenesis of NAFLD are still poorly understood. The key 
factors in the progress of NAFLD are still not clearly defined. In recent years, many litera-
ture sources have reported the pathogenesis of NAFLD, mainly including two-hit (Fig. 2, 
red frame) (7), and multiple parallel hit (Fig. 2, blue frame) (8, 9) hypotheses.
The first hit is the development of hepatic steatosis while the second hit includes cel-
lular stresses such as oxidative stress, apoptosis stress and gut-derived lipopolysaccharide 
stress (LPS). In these two hypotheses, insulin resistance is regarded as the most important 
Fig. 1. Natural history of nonalcoholic fatty liver disease. NAFLD – nonalcoholic fatty liver disease, 
NASH – non-alcoholic steatohepatitis, HCC – hepatocellular carcinoma.
Fig. 2. The two hits hypothesis and the multiple parallel hits hypothesis.
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factor. In the two-hits hypothesis, hepatic steatosis develops after a first hit and progresses 
to NAFLD by a subsequent hit including cellular stresses (such as oxidative stress, gut- 
-derived lipopolysaccharide stress, etc.). Although fatty liver is usually non-progressive, it 
can progress in patients harboring the risk allele of many genes that play an important role 
in the development of NASH, such as patatin-like phospholipase 3 (PNPLA3) (10). Thus, the de-
velopment of NAFLD is regarded a multiple hit process.
In the parallel hits hypothesis, there are multiple parallel hits, such as fasting-induced 
adipose factor, adipocytokines, certain proinflammatory cytokines, etc. (see details in Fig. 
2). Hepatic steatosis occurs due to the imbalance between triglyceride accumulation and 
elimination in the liver. Insulin resistance (IR) is closely and frequently related to the de-
velopment of NAFLD because it can alter nutrient metabolism (11). Hepatic inflammation 
is caused by the increase of many inflammatory cytokines, such as interleukin 6 (IL6), 
tumor necrosis factor TNF, etc. It can be also caused by a decrease of many anti-inflam-
matory cytokines, such as adiponectin (12).
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
There are many important regulators among the main discovered mechanisms. Per-
oxisome proliferator-activated receptor (PPAR) is one of these factors. PPARs are associ-
ated with nutrient metabolism and cellular proliferation. There are four subtypes in the 
PPAR family, namely, PPAR, PPAR, PPAR and PPAR. PPAR (NR1C1) is highly ex-
pressed in the tissues with high fatty acid oxidation such as liver (13). PPAR/ (NR1C2) is 
highly expressed in liver, cardiac, kidney and skeletal muscles, brain, adipose tissues, co-
lon and vasculature (14). PPAR (NR1C3) is highly expressed in adipose tissues (15). 
PPAR plays an important role in the transcription process, glucose metabolisms and other 
events (16).
PPARs are nuclear receptors that are parts of the steroid, retinoid, and thyroid hor-
mone receptor superfamily of ligand-activated transcription factors (16, 17). PPAR iso-
forms have four functional domains, termed A/B domain, DNA-binding domain (DBD), 
hinge domain (HD) and ligand-binding domain (LBD). Among these domains, the A/B 
domain contains the activation function (AF)-1 and is ligand-independent. AF-1 plays an 
important role in the progress of kinase phosphorylation. DBD domain contains two high-
ly conserved zinc finger motifs and promotes the binding of receptors to a DNA sequence 
in the promoter region of target genes. It is known as the peroxisome proliferator response 
element (PPRE). The HD domain acts as a docking site used for cofactors. The LBD is re-
sponsible for ligand specificity and increases target gene transactivation (18) (see details in 
Fig. 3).
Due to the important role of PPARs in the treatment of NAFLD, researchers have paid 
great attention to drug discovery based on PPARs, especially PPAR agonists. As shown 
below, there are two main mechanisms of PPAR agonists.
PPAR agonists and insulin resistance in NAFLD
As insulin resistance is the major mechanism in the progression of NAFLD, many 
researchers and physicians are paying increasing attention to the potential therapeutic 
effects of insulin sensitizers. Insulin binds with its specific receptor and activates the in-
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tracellular signaling pathway. Insulin receptor then phosphorylates itself and insulin re-
ceptor family members such as IRS1 and IRS2. IRS1 and IRS2 regulate insulin homeostasis 
by mediating insulin signaling and inducing insulin sensitivity in the liver (19). Insulin 
resistance (IR) has been demonstrated in many research reports to lead to inflammation 
and inflammatory response in the progress of NAFLD (20).
Thiazolidinediones (TZDs) contain two heteroatoms, nitrogen and sulfur. They can 
activate the nuclear transcription factor named peroxisome proliferator-activated receptor 
gamma (PPARγ). PPARγ can upregulate specific genes that decrease insulin resistance, inflam-
mation, proliferation, etc., and increase insulin sensitivity. Among them, the representatives of 
TZDs are troglitazone, rosiglitazone and pioglitazone. In addition to being reported as cancer 
treatment drugs, they have also been approved for the treatment of diabetes mellitus type II 
(21). Clinically, troglitazone is the first TZD that is widely used in the treatment for diabe-
tes. The first clinical study revealed that seven of ten NASH patients who received trogli-
tazone (400 mg per day for 6 months) normalized alanine aminotransferase (ALT) at the 
end of the treatment (22).
Ample data have suggested the potential therapeutic effects of TZDs on NAFLD and 
liver steatosis, presumably due to their action of decreasing insulin resistance, beneficial 
effects of glucose, etc. (23, 24). As far as rosiglitazone and pioglitazone are concerned, many 
researchers have demonstrated that they show severe side effects, such as cardiovascular 
morbidity of rosiglitazone and facilitation of bladder cancer of pioglitazone (24, 25). Ac-
cording to the PROspective poplitazone (PROactive) clinical trial database, pioglitazone 
reduced cardiovascular complications compared to the control patients (26).
PPAR agonists and inflammation in NAFLD
As confirmed by many researchers, along with insulin resistance, inflammation has 
also been demonstrated to be a key pathway in the development of hepatic diseases such 
as NAFLD. Hepatic pro-inflammatory cytokines are also regarded as important markers of 
the increasing severity of liver disease, such as transcription factor NF-B, etc. (23). NF-B 
plays a crucial role in the process of inflammation chain, including cellular proliferation, 
chemokines, etc. (27). Many literature sources have revealed that insulin resistance could 
Fig. 3. Schematic structure of peroxisome proliferator-activated receptor (PPARs).
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enhance inflammation in NAFLD/NASH. Also, inflammation could disrupt insulin signal-
ing, for example, serine phosphorylation of insulin receptor substrate by inflammatory 
signal transducers such as NF-B inhibitor (27). Interleukin 6 (IL-6) is an interleukin that 
acts both as a pro-inflammatory cytokine and an anti-inflammatory myokine. In humans, 
it is encoded by the IL6 gene, a target gene of NF-B, and its expression was more than 100-
fold higher in adipose tissue compared to its expression in liver tissue (28). On the other 
hand, another important inflammatory factor in NAFLD patients is the tumor necrosis fac-
tor (TNF-). Researchers have demonstrated that the severity of NAFLD might be associ-
ated with the increased level of TNF- in NAFLD patients (29, 30). TNF could bind to 
trimerized TNF receptor type I and activate NF-B via the inhibitor of the nuclear factor 
kappa-B kinase (IKK) pathway. TNF- could induce c-Jun N-terminal kinase (JNK) activa-
tion, which is associated with the induction of hepatocyte death (31, 32). On the other hand, 
Lv and his colleagues (33) found that TNF- could directly induce lipid accumulation 
through the AMP-activated protein kinase (AMPK) pathway, which is known as an impor-
tant factor in the process of energy homeostasis. In addition, lipopolysaccharides (LPS) 
could induce activation of mitogen-activated protein kinases (MAPKs) and liver injury (28).
All studies have clearly revealed that inflammatory factors are important regulators 
involved in NAFLD/NASH. Hence, suppressing inflammation might be an attractive ther-
apeutic approach for improving inflammatory liver disease and the associated insulin 
resistance. Recent studies have shown that PPARs could produce anti-inflammatory ef-
fects. PPARs could accelerate lipid catabolism, which might reduce liver steatosis. Many 
experiments have revealed that PPAR agonists could attenuate the symptoms of NAFLD/
NASH (33). Mechanisms of the beneficial metabolic effects of PPAR activation may be the 
following: (i) insulin resistance associated with pro-inflammatory microenvironment, (ii) 
effects of the tumor necrosis factor-alpha (TNF) in adipocytes, (iii) activation of cytokine-
mediated signaling (e.g., via NF-B) enhancing insulin action, (iv) reducing circulating lev-
els of proteins that serve as markers of inflammation, (v) inducing the expression of adipo-
nectin implicated as having anti-inflammatory activity (see details in Fig. 4).
Fig. 4. PPARs regulate the inflammation in the NAFLD.
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Based on the above mentioned important role of PPARs in NAFLD, researchers and 
clinicians have discovered many PPAR agonists besides the above mentioned ones. Thus, 
according to the different subtypes of PPARs, we have summarized all the PPAR agonists 
that have been reported (see Table I).
PPAR
N-3 polyunsaturated fatty acids (n-3 PUFAs) are PPAR α-ligands. PUFA can amelio-
rate insulin sensitivity through binding PPAR  Patients treated with n-3 PUFA showed 
reduction of triglyceride and alanine transaminase (ALT) serum levels (27, 34–37). Oleoyle-
thanolamine (OEA) has been demonstrated as an endogenous high-affinity PPAR. Re-
searchers have revealed that 5 mg kg–1 per day OEA (i.p.) could ameliorate the development 
of NAFLD compared to control groups after treatment for 6 weeks through detecting the 
levels of plasma triglycerides (TG), serum total cholesterol (TC), alanine aminotransferase 
(ALT) and aspartate transaminase (AST) as well as liver inflammatory cytokines (38).
Another classic agonist of PPAR is fenofibrate. Fenofibrate could activate lipolytic 
enzymes, reduce the synthesis of apolipoprotein and remove plasma triglycerides. Fenofi-
brate is widely used for the treatment of NAFLD. Fenofibrate has been demonstrated to 
protect against inflammatory injury in NAFLD. The probable mechanism is associated 
with the endoplasmic reticulum (ER) stress pathway (39). In another report, researchers 
divided mice into two groups (fructose-fed and fructose-fenofibrate treated groups). The 
results revealed that after the treatment with 100 mg kg–1 (p.o.), fatty acids (FAs) and very 
low-density lipoprotein (VLDL), secretions were decreased more than in the control group 
(40). In a clinical trial, Piyush Patel et al. (41) found that the TG level was reduced in patients 
who were administered fenofibrate (116 patients were administered choline fenofibrate 
and 116 patients were administered micronized fenofibrate). Another research group also 
found that adding pentoxifylline to fenofibrate had a beneficial effect on a direct marker 
linked to matrix deposition (hyaluronic acid), a cytokine/growth factor linked to liver fi-
brosis (transforming growth factor beta 1), the inflammatory pathway, insulin resistance 
and liver stiffness, in non-alcoholic fatty liver patients treated with fenofibrate (300 mg 
daily) plus pentoxifylline (1200 mg per day) for 24 weeks (42).
In some publications, however, researchers reported that fenofibrate exerted side ef-
fects, such as nephrotoxicity (leading to renal vasoconstriction) (43) and hepatotoxicity 
(enhanced the fatty liver mass) (44).
PPAR
GW4064 is a PPAR agonist that has highly selective farnesoid X receptor (FXR) affin-
ity. FXR is a member of the nuclear receptor superfamily of ligand activated receptors and 
is mainly expressed in the liver, intestines, kidneys and adrenal glands. FXR has been 
found to be a key regulator of lipid metabolism and to improve peripheral insulin sensitiv-
ity. Xin et al. (45) found that GW4064 could increase the expression of adiponectin, leptin, 
adiponectin receptor 2 (AdipoR2) and leptin receptors (OB-Rb).
Chehaibi et al. (46) found that GW0742 is another PPAR agonist and could upregu-
late serum HDL-C and HDL phospholipids in NAFLD mice. The effects of GW0742 could 
be completely abolished in PPAR--deficient mice (45). GW501516 could prevent endo-
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plasmic-reticulum (ER) stress associated with inflammation and insulin resistance. The 
published data showed that the mechanisms might be related to activation of the AMP 
activated protein kinase (AMPK) pathway and inhibition of the extracellular-signal-regu-
lated kinase (ERK)1/2 pathway (46).
PPAR
PPARγ plays an indispensable role in adipogenesis, which is frequently impaired un-
der pathological conditions such as nonalcoholic fatty liver disease (NAFLD) or nonalco-
holic steatohepatitis (NASH). Many drugs were developed based on the activation of 
PPAR, such as telmisartan (47), rivoglitazone (48), etc.
Table I. PPAR agonists








































Inhibition of hepatic 
gluconeogenesis and 
anti-inflammatory





mediated control of 
glucose and FFA fluxes
Not reported 52, 57
PPAR GW501516 Anti-inflammatory Not reported 58
PPAR Alkoxy-3-
indolylacetic acid
Inhibition of the level of 
hepatic triglycerides
Not reported 59
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Rivoglitazone is a novel agonist of PPAR that has been demonstrated in rats and 
monkeys. It has significant stereoselectivity and is very efficacious. Rivoglitazone could 
enhance adiponectin levels in plasma and decrease adipose mRNA levels in mice. Rivo-
glitazone could also ameliorate insulin resistance (49). In clinics, rivoglitazone has been 
used to treat type 2 diabetes, but rivoglitazone has many adverse effects such as periph-
eral edema and weight gain (50).
Dual PPAR agonist
GFT505 is a PPAR agonist with preferential activity on PPARα with half-maximal ef-
fective concentration of about 10–20 nmol L–1 and additional activity on PPARδ with half-
maximal effective concentration of about 100–150 nmol L–1. Researchers have found that 
GFT505 could improve glycemic control in db/db mice, which is related to its liver-centric 
effects on hepatic insulin sensitivity and gluconeogenesis (49). Also, in phase II of clinical 
studies, researchers found that GFT505 treatment decreased alanine aminotransferase, 
gamma-glutamyl transpeptidase and alkaline phosphatase (51). Shiomi et al. (36) found 
that Z-551, having both PPARα and PPARγ antagonistic activities, could increase the level 
of molecules involved in fatty acid combustion and thus significantly reduce fasting plas-
ma levels of glucose, triglycerides, free fatty acids, insulin and leptin. This indicated that 
Z-551 might be clinically useful for preventing or treating metabolic disorders such as type 
2 diabetes, dyslipidemia and NAFLD (52).
Zhao et al. (53) found that osthole might be a dual agonist of PPAR α/γ and could de-
crease hepatic lipid accumulation. After treating the rats with 5–20 mg kg–1 osthole for 4 
weeks, the results showed that the serum alanine aminotransferase, aspartate aminotrans-
ferase, total cholesterol, triglyceride, and free fatty acid levels, tumor necrosis factor-α 
(TNF-α) and liver index were lower in the osthole treated group than in the control group. 
This demonstrated that osthole was effective in treating rat steatohepatitis (36).
CURRENT PROBLEMS
Although many researchers have revealed the molecular mechanism in the develop-
ment of NAFLD such as inflammation, the basic and clinical trials are still needed to face 
additional challenges. Thus far, PPARs have been considered as effective molecular targets 
that could be used to treat liver disease. However, they also need more clinical evidence 
before their clinical application. For example, insulin sensitizer might induce some side 
effects, such as heart attack, heart failure, weight gain, etc. (60). The adverse effects of each 
PPAR agonist are summarized in Table I. In order to overcome these adverse effects, many 
researchers found that dual PPAR agonists could improve liver injury without side effects 
induced by single PPAR agonists (13, 61–63). Clinical trials also demonstrated that PPAR 
agonist therapies may lead to side effects such as paradoxical dissociation of steatosis, in-
flammation, etc. Thus, much work still remains to be done to fully cure the NAFLD in or-
der to separate the beneficial effects of PPAR agonists from unwanted side effects.
CONCLUSIONS
In this review, we focused on and outlined the PPAR agonists in the treatment of 
NAFLD. Elucidating detailed mechanisms of these drugs could provide new targets for 
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future therapeutic strategies in NAFLD. The effect and safety of NAFLD management 
should be taken into account as well.
In summary, further large-scale clinical trials and practice are needed to verify drug 
treatments.
Acronyms, abbreviations, symbols. – AdipoR2 – adiponectin receptor 2, ALT – alanine 
aminotransferase, AMPK – AMP activated protein kinase, AST – aspartate transaminase, 
DBD – DNA-binding domain, ER – endoplasmic-reticulum, FAs – fatty acids, ERK– extra-
cellular-signal-regulated kinase, FFA – free fatty acid, FXR – farnesoid X receptor, HCC – 
hepatocellular carcinoma, HD – hinge domain, IKK – inhibitor of nuclear factor kappa-B 
kinase, JNK – c-Jun N-terminal kinase, IL6 – interleukin 6, IR – insulin resistance, LBD – 
ligand-binding domain, LPS – lipopolysaccharide, MAPKs – mitogen-activated protein 
kinases, n-3 PUFAs – n-3 polyunsaturated fatty acids, NAFLD – non-alcoholic fatty liver 
disease, NASH – non-alcoholic steato-hepatitis, NF-B – nuclear factor B, OEA – oleoyle-
thanolamine, PNPLA3 – patatin-like phospholipase 3, PPAR – peroxisome proliferator-
activated receptor alpha, PPAR – peroxisome proliferator-activated receptor beta, PPAR 
– peroxisome proliferator-activated receptor delta, PPAR – peroxisome proliferator-acti-
vated receptor gamma, PPARs – peroxisome proliferator-activated receptors, TC – total 
cholesterol, TG – triglyceride, TNF – tumor necrosis factor alpha, TZDs – thiazolidinedio-
nes, VLDL – very low density lipoprotein.
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